| Not Yet Recruiting | Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH Participants MASH | Phase 1 / Phase 2 | 2026-12-01 |
| Not Yet Recruiting | Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism | Phase 2 | 2026-06-01 |
| Terminated | Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathy Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Vitamin d Deficiency | Phase 3 | 2023-01-31 |
| Completed | Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19 COVID-19, Coronavirus, SARS-CoV2 Infection | Phase 2 | 2020-11-02 |
| Completed | Quality of Life and Visual Acuity of Visglyc Eye Drops on Dry Eye Patients Dry Eye Syndromes, Cataract | N/A | 2019-05-30 |
| Completed | A Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product Presentations Healthy Male Volunteers | Phase 1 | 2019-01-18 |
| Completed | Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Ja Vitamin D Insufficiency, Secondary Hyperparathyroidism | Phase 1 | 2018-08-20 |
| Terminated | Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI Secondary Hyperparathyroidism Due to Renal Causes, Chronic Kidney Diseases, Vitamin D Deficiency | Phase 2 | 2018-07-09 |
| Completed | Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency, CKD Stage 3 | Phase 4 | 2018-06-08 |
| Completed | Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects Type 2 Diabetes Mellitus | Phase 2 | 2018-04-02 |
| Terminated | Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Benign Prostatic Hyperplasia | Phase 2 | 2018-02-21 |
| Completed | Efficacy and Safety of a Intra-articular Injection, ENKO1, in Patients With Symptomatic Knee Osteoarthritis. Osteoarthritis, Knee | N/A | 2017-12-15 |
| Completed | Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency Growth Hormone Deficiency | Phase 3 | 2017-12-07 |
| Completed | 4Kscore Using Serum Stored Uncentrifuged Prostate Cancer | — | 2017-10-04 |
| Completed | A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male Hemophilia A or B With Inhibitors | Phase 1 | 2017-01-22 |
| Completed | Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children Pediatric Growth Hormone Deficiency | Phase 3 | 2016-12-01 |
| Completed | A Single-dose, Dose-escalation Study of a Long-acting MOD-6031 in Healthy Overweight or Obese Subjects Obesity | Phase 1 | 2016-02-01 |
| Completed | A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B Hemophilia A, Hemophilia B | Phase 1 | 2015-05-01 |
| Completed | Efficacy and Tolerability of a Nutritional Supplement, Plactive Progen, in ACL Reconstruction ACL Reconstruction | N/A | 2015-03-09 |
| Completed | Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Growth Hormone Deficiency | Phase 1 | 2015-01-01 |
| Completed | Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoled Breast Cancer, Prostate Cancer, Bone Neoplasms | Phase 1 | 2014-12-01 |
| Terminated | A Study of LY2944876 in Healthy Japanese and Non-Japanese Participants Healthy Volunteers | Phase 1 | 2014-07-01 |
| Completed | A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 D Diabetes Mellitus, Type 2 | Phase 2 | 2014-04-01 |
| Completed | Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children Growth Hormone Deficiency (GHD) | Phase 2 | 2014-02-01 |
| Completed | A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia Down Syndrome | Phase 2 | 2013-09-01 |
| Terminated | A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone Def Adult Growth Hormone Deficiency | Phase 3 | 2013-06-01 |
| Completed | Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002 Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency | Phase 3 | 2013-04-01 |
| Terminated | A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease Alzheimer's Disease | Phase 2 | 2013-01-01 |
| Withdrawn | Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018) Stage 5 Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT), Hemodialysis (HD) | Phase 2 | 2013-01-01 |
| Completed | Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease Alzheimer's Disease | Phase 2 | 2012-11-01 |
| Terminated | Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder Bipolar 1 Disorder | Phase 2 | 2012-08-01 |
| Completed | Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children Pediatric Growth Hormone Deficiency | Phase 2 | 2012-02-01 |
| Completed | Effects of TT301 on Cytokine Levels Post Endotoxin Challenge Traumatic Brain Injury | Phase 1 | 2011-05-01 |
| Completed | Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT) Chronic Kidney Disease, Secondary Hyperparathyroidism, Vitamin D Insufficiency | Phase 2 / Phase 3 | 2010-10-01 |
| Completed | MOD-4023 (Long-Lasting Human Growth Hormone (hGH)) Study in Growth Hormone Deficient Adults (GHDA) Adult Growth Hormone Deficiency | Phase 2 | 2010-08-01 |
| Withdrawn | Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON) Age Related Macular Degeneration | Phase 3 | 2009-11-01 |
| Completed | MOD-4023 Study in Healthy Male Volunteers Healthy | Phase 1 | 2009-10-01 |
| Completed | ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease Alzheimer's Disease | Phase 2 | 2009-06-01 |
| Completed | A Prospective, Multicenter, Open-label, Safety and Preliminary Efficacy Study of the Surgical Implantation of Glaucoma | N/A | 2009-01-01 |
| Completed | A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione Diabetes Mellitus, Type 2 | Phase 2 | 2008-08-01 |
| Completed | ELND005 in Patients With Mild to Moderate Alzheimer's Disease Alzheimer Disease | Phase 2 | 2007-12-01 |
| Terminated | Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD Macular Degeneration | Phase 3 | 2007-08-01 |
| Completed | Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis Psoriasis | Phase 2 | 2006-09-01 |
| Completed | Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema Diabetic Macular Edema | Phase 2 | 2006-01-01 |
| Completed | A Study in Type 2 Diabetic Patients With Repeated Doses of E1 in Combination With G1 Type 2 Diabetes | Phase 1 | 2005-09-01 |
| Completed | Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin Chronic Hepatitis C, Hepatitis, Viral, Human | Phase 1 | 2005-08-01 |
| Completed | Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Relate Macular Degeneration | Phase 2 | 2005-07-01 |
| Completed | A Study in Type 1 Diabetic Patients With Repeated Doses of E1 in Combination With G1 Type 1 Diabetes | Phase 1 | 2005-06-01 |
| Completed | Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5 Macular Degeneration | Phase 1 | 2004-08-01 |